Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)

Post‐surgical weight loss influences chemotherapy compliance and may be a risk factor for survival. Intake of an oral elemental nutritional supplement (OENS) can reduce weight loss after gastric cancer (GC) surgery. We assessed whether therapy completion levels would increase in patients receiving postoperative adjuvant chemotherapy in combination with an OENS.

[1]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Chad A. LaGrange,et al.  Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  H. Imamura,et al.  Long‐term effects of an oral elemental nutritional supplement on post‐gastrectomy body weight loss in gastric cancer patients (KSES002) , 2019, Annals of gastroenterological surgery.

[4]  G. Lyman,et al.  Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer , 2019, Supportive Care in Cancer.

[5]  H. Kuwano,et al.  A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. , 2019, Surgical oncology.

[6]  Gang Zhao,et al.  Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. , 2019, JAMA.

[7]  Y. Kodera,et al.  Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Kazuhiro Yoshida,et al.  Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy , 2018, Annals of Surgical Oncology.

[9]  R. Wenham,et al.  Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. , 2018, Gynecologic oncology.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  T. Yoshikawa,et al.  Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer , 2017, International Journal of Clinical Oncology.

[12]  H. Imamura,et al.  Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial , 2016, Annals of Surgical Oncology.

[13]  E. Oki,et al.  A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Kazuhiro Yoshida,et al.  Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study , 2016, Gastric Cancer.

[15]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[16]  A. Ejaz,et al.  Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. , 2014, Journal of the American College of Surgeons.

[17]  F. Qi,et al.  Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis , 2014, Scandinavian journal of gastroenterology.

[18]  F. Ciardiello,et al.  Treatment of gastric cancer. , 2014, World journal of gastroenterology.

[19]  T. Yoshikawa,et al.  Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer , 2013, Annals of Surgical Oncology.

[20]  D. Park,et al.  Safety, compliance, and predictive parameters for dosage modification in adjuvant S‐1 chemotherapy for gastric cancer , 2013, Cancer science.

[21]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[22]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Wilke,et al.  Treatment strategies in gastric cancer. , 2011, Deutsches Arzteblatt international.

[24]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[25]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[26]  Kazuhiro Yoshida,et al.  Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy , 2015, Gastric Cancer.

[27]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[28]  Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.

[29]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.

[30]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .